MGMT and glioblastoma: Additionally, monocyte antigen carrier cells have shown potential in the treatment of newly diagnosed GBM with an unmethylated MGMT gene promoter, such as the MT-201-GBM vaccine, which is made from a patient’s own cells loaded with CMV pp65-LAMP mRNA and which has been in clinical trials since August 2023 to determine its maximum tolerated dose (NCT04741984).